Best practices for evaluation of bone marrow in nonclinical toxicity studies

William J Reagan1, Armando Irizarry-Rovira, Florence Poitout-Belissent

  • 1Pfizer, Inc., Groton, Connecticut, USA. william.j.reagan@pfizer.com

Toxicologic Pathology
|February 9, 2011
PubMed